(Hypertension. 2000;35:587.)
© 2000 American Heart Association, Inc.
Scientific Contributions |
Blood Pressure–Independent Effects in Rats With Human Renin and Angiotensinogen Genes
From the Franz Volhard Clinic, Medical Faculty of the Charité, Humboldt University of Berlin (Germany) (E.M., D.N.M., F.S., J-K.P., V.G., H.H., F.C.L.); Institute of Biomedicine, University of Helsinki (Finland) (E.M); Max Delbrück Center for Molecular Medicine, Berlin, Germany (M.B., D.G., H.H., F.C.L.); dF. Hoffmann–La Roche, Basel, Switzerland (V.B.); and Institute for Clinical Pharmacology, Universitätsklinikum-Benjamin Franklin, Free University of Berlin (Germany) (D.G.).
Correspondence to Friedrich C. Luft, Franz Volhard Clinic, Wiltberg Strasse 50, 13125 Berlin, Germany. E-mail luft{at}fvk-berlin.d
Abstract—The blood
pressure–independent effects of angiotensin II (Ang II)
were examined in double transgenic rats (dTGR) harboring human renin
and human angiotensinogen genes, in which the end-organ
damage is due to the human components of the renin
angiotensin system. Triple-drug therapy
(hydralazine 80 mg/L, reserpine 5 mg/L, and
hydrochlorothiazide 25 mg/L in drinking water) was
started immediately after weaning. Triple-drug therapy normalized blood
pressure and coronary resistance, only partially prevented
cardiac hypertrophy, and had no effect on ratio of renal
weight to body weight. Although triple-drug therapy delayed the onset
of renal damage, severe albuminuria nevertheless occurred.
Semiquantitative scoring of ED-1–positive and MIB-5–positive (nuclear
cell proliferation–associated antigen Ki-67) cells showed profound
perivascular monocyte/macrophage infiltration and cell
proliferation in kidneys and hearts of untreated dTGR. Triple-drug
therapy had only a minimal effect on local inflammatory response or
vascular cell proliferation. In contrast, a novel orally active human
renin inhibitor (HRI), 30 mg/kg by gavage for 4 weeks,
normalized blood pressure and coronary resistance and also
prevented cardiac hypertrophy and albuminuria.
ED-1–positive cells and MIB-5–positive cells were decreased by HRI in
hearts and kidneys almost to levels observed in normotensive
Sprague-Dawley rats. The renoprotective effects of HRI were at least in
part due to improved renal hemodynamics and distal
tubular function, since HRI shifted renal
pressure-diuresis/natriuresis curves leftward by 
35
mm Hg, increased glomerular filtration rate and
renal blood flow, and shifted the fractional water and sodium excretion
curves leftward. In untreated dTGR, plasma Ang II was increased by
400% and renal Ang II level was increased by 300% compared with
Sprague-Dawley rats. HRI decreased plasma human renin activity by 95%
and normalized Ang II levels in both plasma and kidney compared with
triple-drug therapy. Our findings indicate that in dTGR harboring human
renin and angiotensinogen genes, Ang II causes end-organ
damage and promotes inflammatory response and cellular growth largely
independent of blood pressure.
Key Words: renin • angiotensinogen • angiotensin II • albuminuria • cell proliferation • natriuresis
This article has been cited by other articles:
 |
|
 |
|
  J.-K. Park, S. Theuer, T. Kirsch, C. Lindschau, U. Klinge, A. Heuser, R. Plehm, M. Todiras, P. Carmeliet, H. Haller, et al. Growth Arrest Specific Protein 6 Participates in DOCA-Induced Target-Organ Damage Hypertension, August 1, 2009; 54(2): 359 - 364. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Ohashi, T. Yamamoto, Y. Huang, T. Misaki, H. Fukasawa, H. Suzuki, A. Togawa, S. Suzuki, Y. Fujigaki, T. Nakagawa, et al. Intrarenal RAS activity and urinary angiotensinogen excretion in anti-thymocyte serum nephritis rats Am J Physiol Renal Physiol, November 1, 2008; 295(5): F1512 - F1518. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Feldt, U. Maschke, R. Dechend, F. C. Luft, and D. N. Muller The Putative (Pro)renin Receptor Blocker HRP Fails to Prevent (Pro)renin Signaling J. Am. Soc. Nephrol., April 1, 2008; 19(4): 743 - 748. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Fischer, R. Dechend, F. Qadri, M. Markovic, S. Feldt, F. Herse, J.-K. Park, A. Gapelyuk, I. Schwarz, U. B. Zacharzowsky, et al. Dietary n-3 Polyunsaturated Fatty Acids and Direct Renin Inhibition Improve Electrical Remodeling in a Model of High Human Renin Hypertension Hypertension, February 1, 2008; 51(2): 540 - 546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Yagi, K.-i. Aihara, Y. Ikeda, Y. Sumitomo, S. Yoshida, T. Ise, T. Iwase, K. Ishikawa, H. Azuma, M. Akaike, et al. Pitavastatin, an HMG-CoA Reductase Inhibitor, Exerts eNOS-Independent Protective Actions Against Angiotensin II Induced Cardiovascular Remodeling and Renal Insufficiency Circ. Res., January 4, 2008; 102(1): 68 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Fischer, R. Dechend, A. Gapelyuk, E. Shagdarsuren, K. Gruner, A. Gruner, P. Gratze, F. Qadri, M. Wellner, A. Fiebeler, et al. Angiotensin II-induced sudden arrhythmic death and electrical remodeling Am J Physiol Heart Circ Physiol, August 1, 2007; 293(2): H1242 - H1253. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Dechend, E. Shagdarsuren, P. Gratze, A. Fiebeler, B. Pilz, S. Meiners, W. Derer, D. L Feldman, R. Webb, and D. N Muller Low-dose renin inhibitor and low-dose AT1-receptor blocker therapy ameliorate target-organ damage in rats harbouring human renin and angiotensinogen genes Journal of Renin-Angiotensin-Aldosterone System, June 1, 2007; 8(2): 81 - 84. [Abstract] [PDF]
|
|
|
|
|
|
J.-K. Park, R. Fischer, R. Dechend, E. Shagdarsuren, A. Gapeljuk, M. Wellner, S. Meiners, P. Gratze, N. Al-Saadi, S. Feldt, et al. p38 Mitogen-Activated Protein Kinase Inhibition Ameliorates Angiotensin II-Induced Target Organ Damage Hypertension, March 1, 2007; 49(3): 481 - 489. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Menne, J.-K. Park, R. Agrawal, C. Lindschau, J. T. Kielstein, T. Kirsch, A. Marx, D. Muller, F. H. Bahlmann, M. Meier, et al. Cellular and molecular mechanisms of tissue protection by lipophilic calcium channel blockers FASEB J, May 1, 2006; 20(7): 994 - 996. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Elmarakby, J. E. Quigley, D. M. Pollock, and J. D. Imig Tumor Necrosis Factor {alpha} Blockade Increases Renal Cyp2c23 Expression and Slows the Progression of Renal Damage in Salt-Sensitive Hypertension Hypertension, March 1, 2006; 47(3): 557 - 562. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Vidal, Y. Sun, S. K. Bhattacharya, R. A. Ahokas, I. C. Gerling, and K. T. Weber Calcium paradox of aldosteronism and the role of the parathyroid glands Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H286 - H294. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. C. Miner and W. L. Miller A Look Between the Cardiomyocytes: The Extracellular Matrix in Heart Failure Mayo Clin. Proc., January 1, 2006; 81(1): 71 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Shagdarsuren, M. Wellner, J.-H. Braesen, J.-K. Park, A. Fiebeler, N. Henke, R. Dechend, P. Gratze, F. C. Luft, and D. N. Muller Complement Activation in Angiotensin II-Induced Organ Damage Circ. Res., September 30, 2005; 97(7): 716 - 724. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Pilz, E. Shagdarsuren, M. Wellner, A. Fiebeler, R. Dechend, P. Gratze, S. Meiners, D. L. Feldman, R. L. Webb, I. M. Garrelds, et al. Aliskiren, a Human Renin Inhibitor, Ameliorates Cardiac and Renal Damage in Double-Transgenic Rats Hypertension, September 1, 2005; 46(3): 569 - 576. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Yoneda, H. Sanada, J. Yatabe, S. Midorikawa, S. Hashimoto, M. Sasaki, T. Katoh, T. Watanabe, P. M. Andrews, P. A. Jose, et al. Differential Effects of Angiotensin II Type-1 Receptor Antisense Oligonucleotides on Renal Function in Spontaneously Hypertensive Rats Hypertension, July 1, 2005; 46(1): 58 - 65. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. T. Weber From Inflammation to Fibrosis: A Stiff Stretch of Highway Hypertension, April 1, 2004; 43(4): 716 - 719. [Full Text] [PDF]
|
|
|
|
 |
|
 D. N. Muller, J. Theuer, E. Shagdarsuren, E. Kaergel, H. Honeck, J.-K. Park, M. Markovic, E. Barbosa-Sicard, R. Dechend, M. Wellner, et al. A Peroxisome Proliferator-Activated Receptor-{alpha} Activator Induces Renal CYP2C23 Activity and Protects from Angiotensin II-Induced Renal Injury Am. J. Pathol., February 1, 2004; 164(2): 521 - 532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G Friedrich, B. Dahlof, U. Sechtem, T. Unger, M. Knecht, R. Dietz, and TELMAR Investigators Telmisartan Effectiveness on Left ventricular MAss Reduction (TELMAR) as assessed by magnetic resonance imaging in patients with mild-to-moderate hypertension -- a prospective, randomised, double-blind comparison of telmisartan with metoprolol over a period of six months -- rationale and study design Journal of Renin-Angiotensin-Aldosterone System, December 1, 2003; 4(4): 234 - 243. [Abstract] [PDF]
|
|
|
|
|
|
P. N. Chander, R. Rocha, J. Ranaudo, G. Singh, A. Zuckerman, and C. T. Stier Jr. Aldosterone Plays a Pivotal Role in the Pathogenesis of Thrombotic Microangiopathy in SHRSP J. Am. Soc. Nephrol., August 1, 2003; 14(8): 1990 - 1997. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Finckenberg, K. Inkinen, J. Ahonen, S. Merasto, M. Louhelainen, H. Vapaatalo, D. Muller, D. Ganten, F. Luft, and E. Mervaala Angiotensin II Induces Connective Tissue Growth Factor Gene Expression via Calcineurin-Dependent Pathways Am. J. Pathol., July 1, 2003; 163(1): 355 - 366. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. N. Muller, A. Mullally, R. Dechend, J.-K. Park, A. Fiebeler, B. Pilz, B.-M. Loffler, D. Blum-Kaelin, S. Masur, H. Dehmlow, et al. Endothelin-Converting Enzyme Inhibition Ameliorates Angiotensin II-Induced Cardiac Damage Hypertension, December 1, 2002; 40(6): 840 - 846. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. N. Muller, E. Shagdarsuren, J.-K. Park, R. Dechend, E. Mervaala, F. Hampich, A. Fiebeler, X. Ju, P. Finckenberg, J. Theuer, et al. Immunosuppressive Treatment Protects Against Angiotensin II-Induced Renal Damage Am. J. Pathol., November 1, 2002; 161(5): 1679 - 1693. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Kaergel, D. N. Muller, H. Honeck, J. Theuer, E. Shagdarsuren, A. Mullally, F. C. Luft, and W.-H. Schunck P450-Dependent Arachidonic Acid Metabolism and Angiotensin II-Induced Renal Damage Hypertension, September 1, 2002; 40(3): 273 - 279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-K. Park, A. Fiebeler, D. N. Muller, E. M.A. Mervaala, R. Dechend, F. Abou-Rebyeh, F. C. Luft, and H. Haller Lacidipine Inhibits Adhesion Molecule and Oxidase Expression Independent of Blood Pressure Reduction in Angiotensin-Induced Vascular Injury Hypertension, February 1, 2002; 39(2): 685 - 689. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. F. Hilgers, A. Hartner, M. Porst, R. Veelken, and J. F.E. Mann Angiotensin II Type 1 Receptor Blockade Prevents Lethal Malignant Hypertension: Relation to Kidney Inflammation Circulation, September 18, 2001; 104(12): 1436 - 1440. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Dechend, A. Fiebeler, J.-K. Park, D. N. Muller, J. Theuer, E. Mervaala, M. Bieringer, D. Gulba, R. Dietz, F. C. Luft, et al. Amelioration of Angiotensin II-Induced Cardiac Injury by a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor Circulation, July 31, 2001; 104(5): 576 - 581. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hannken, R. Schroeder, R. A. K. Stahl, and G. Wolf Atrial natriuretic peptide attenuates ANG II-induced hypertrophy of renal tubular cells Am J Physiol Renal Physiol, July 1, 2001; 281(1): F81 - F90. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. A. Mervaala, Z. J. Cheng, I. Tikkanen, R. Lapatto, K. Nurminen, H. Vapaatalo, D. N. Muller, A. Fiebeler, U. Ganten, D. Ganten, et al. Endothelial Dysfunction and Xanthine Oxidoreductase Activity in Rats With Human Renin and Angiotensinogen Genes Hypertension, February 1, 2001; 37(2): 414 - 418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. J. Cheng, T. Vaskonen, I. Tikkanen, K. Nurminen, H. Ruskoaho, H. Vapaatalo, D. Muller, J.-K. Park, F. C. Luft, and E. M. A. Mervaala Endothelial Dysfunction and Salt-Sensitive Hypertension in Spontaneously Diabetic Goto-Kakizaki Rats Hypertension, February 1, 2001; 37(2): 433 - 439. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. C. Luft Workshop: Mechanisms and Cardiovascular Damage in Hypertension Hypertension, February 1, 2001; 37(2): 594 - 598. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. N. Muller, E. M. A. Mervaala, F. Schmidt, J.-K. Park, R. Dechend, E. Genersch, V. Breu, B.-M. Loffler, D. Ganten, W. Schneider, et al. Effect of Bosentan on NF-{kappa}B, Inflammation, and Tissue Factor in Angiotensin II-Induced End-Organ Damage Hypertension, August 1, 2000; 36(2): 282 - 290. [Abstract] [Full Text] [PDF]
|
|